Bayer Regeneron Eylea News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Korea Biomed has reported that Celltrion Healthcare has won bids to supply Vegzelma®, biosimilar to Genentech’s Avastin® (bevacizumab), in Italy and…

Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029 ResearchAndMarkets.com's offering. Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF). The most frequently used anti-VEGF drugs are Roche/Genentech's humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regeneron's fusion protein Eylea (aflibercept). Angiotensin converting enzyme (ACE) inhibitors can be used to t...